Hamada Rady

Background

About Hamada Rady

I have extensive clinical research experience which include: manage and oversight all the activities and operations of the research Pharmacy which include; planning, organizing, and implementing Standard Operating Procedures (SOPs) in accordance with institutional policies and procedures, and in cooperation with other departments, while following Good Clinical Practice (GCP), FDA and JCAHO requirements; cooperation with different departments and leaderships at the Tulane's school of medicine, HCA hospital, and inpatient pharmacy for initiations and monitoring or clinical trials; interface with pharmaceutical sponsor representatives and designees during monitoring visits and audits; procure, maintain, store, and dispense investigational products under clinical trials protocols; maintain prescriptions and clinical trials dispensing records per applicable federal and state laws; maintain the highest standards for medication safety practices and assuring compliance with local and national regulations and standards to ensure that quality, efficacy, and safety of the results of the study; and performing education activities to pharmacy staff, research coordinators, and floor nurses. I have also years of clinical and operational pharmacy experience. I also serve as a voting member of the Tulane Biomedical IRB committee for which I review human subjects research submitted to the IRB; providing timely written comments on research undergoing IRB review; working with investigators to resolve matters relating to research approval and participation in educational efforts for investigators, research staff, and new IRB members; maintain confidentiality of IRB-related information in accordance with the terms and conditions of the Tulane’s IRB Member Confidentiality Agreement. I have also years of academic research experience for PhD thesis project and post-doctoral fellowship projects that focused mainly on immunology and vaccine development studies. I have also participated in designing multiple investigator-initiated clinical trials.